All In Biotech

Drug Trial Radar · NCT07620938

Clinical Study of TJ0113 Capsule in the Treatment of Patients With Sarcopenia

A Randomized, Double-Blind, Multicenter, Placebo Parallel-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of TJ0113 Capsule in the Treatment of Patients With Sarcopenia

Last checked: Nov 19, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Jun 12, 2026

Primary completion

Aug 22, 2027

Study completion Oct 22, 2027

Sponsor

Lead sponsor
Hangzhou PhecdaMed Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, multicenter, placebo parallel-controlled Phase II clinical study designed to evaluate the clinical efficacy and safety of TJ0113 Capsule in patients with sarcopenia. The entire study plans to enroll 204 participants with sarcopenia. Eligible participants will be stratified by age (\< 70 years or ≥ 70 years to ≤ 80 years or \> 80 years) and block-randomized in a 1:1:1:1 ratio into 4 groups (TJ0113 Capsule 100 mg dose group; TJ0113 Capsule 200 mg dose group; TJ0113 Capsule 400 mg dose group; placebo group), with 51 participants per group. Participants in the placebo group will then be re-randomized in a 1:1:1 ratio to the respective dose groups (100 mg, 200 mg, and 400 mg). After randomization, study participants will receive continuous oral administration for 26 weeks with efficacy and safety evaluations, followed by a 1-week follow-up period after the end of treatment.

Conditions

  • Sarcopenia

Interventions

  • TJ0113Drug

    100mg or 200 mg or 400 mg Capsule, Once Daily

  • TJ0113Drug

    100mg or 200 mg or 400 mg Capsule, Once Daily

  • TJ0113Drug

    100mg or 200 mg or 400 mg Capsule, Once Daily

  • PlaceboDrug

    Capsule, Once Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in gait speed on the 400-meter Walk Test at Week 26Time frame: After 26 weeks of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.